| The Organizing
Committee requires that presenting authors submit their abstracts
electronically via this website. Abstract submissions will only be
accepted from the presenting author. All correspondence regarding
the status of the abstract will only be sent to the presenting author.
As in previous years, the abstract and application process has been
combined into one online step. During the online application/abstract
process, if you indicate on the application form that you are the
presenting author and intend to submit an abstract, you will be forwarded
to the ABSTRACT SUBMISSION page, providing an opportunity to upload
the abstract. There is no need to complete the application/abstract
form until your abstract is ready for submission.
To submit an abstract click on the SUBMIT
ABSTRACT button at the bottom of the page and follow the step-by-step
directions, which will enable you to provide the presenting author
contact information, answer a few questions, and then upload the
file containing your abstract from the computer system that you
are using to access this website. To ensure your abstract retains
any special characters or formatting, the abstract must be in MICROSOFT
WORD format.
Multiple submissions from the same data set
will jeopardize abstract acceptance. The Organizing Committee urges
submission of a single abstract from the entire group involved in
the study.
Each applicant may submit a MAXIMUM of two
(2) abstracts. If more than two (2) abstracts are submitted, only
the first 2 submissions will be evaluated.
The deadline for abstract
submission is Thursday, April 8, 2004.
For each accepted abstract, one registration
slot will be awarded to the presenting author. Co-authors
of abstracts must complete an application to be considered for admittance
into the Workshop.
Notifications of acceptance and format of
presentation (oral or poster presentation) will be sent out on May
4, 2004, via fax. Guidelines for preparing your poster presentations
will be sent if your abstract is accepted.
Upon notification of
acceptance of abstract, the presenting author must REGISTER for
the Workshop by May 18, 2004. Failure to register on or before
the deadline may result in the loss of your acceptance in the Workshop.
Abstract presenters MAY NOT be changed after
acceptance, without consent of the Organizing Committee.
SAMPLE ABSTRACT
To view a sample abstract, click
here. The sample form is an Adobe Acrobat document. If your
computer cannot read the sample, please click
here to download Adobe's free Acrobat Reader.
ABSTRACT GUIDELINES
Format
The publisher of the abstract book does
not allow figures or tables to appear in the submitted abstract.
The body of the uploaded abstract submission
should not exceed 350 words; this limit excludes the title, authors
and affiliations.
- Results and conclusions must be included;
it is not acceptable to state that results will be presented.
- Abstract text may be divided into the
following sections: objectives/aim, methods, results, conclusion(s)/discussion.
- Tables, graphs and references must
NOT be used.
- Acknowledgements may be listed after the
abstract.
- Generic (not trade) names for drugs should
be used and written in full (not denoted by initials).
- Dosing regimens should be written in full.
For example, TID should be written as three times daily.
Clearly define all concepts and abbreviations
at first use. If English is not your primary language, attempt to
have your abstract reviewed by a native English speaker. To be acceptable,
abstracts shall contain a concise statement of the research. It
is recommended that the author follow the structured format below:
Title (not included
in 350 word limit)
Use a short and concise title that indicates the content of the
abstract. Capitalize the first letter of each word except prepositions,
articles, and species names. Species names should be spelled out
at first use. Italicize scientific names of organisms (example:
Staphylococcus aureus). For therapeutic agents, only generic
names may be used (no trade names are permitted in abstract titles).
Authors/Affiliations (not
included in 350 word limit)
Authors' names should be entered using initial(s) for the first
and middle names followed by the full last name, with presenting
author underlined (e.g. AN Author1, AN Author2 and AN Author3).
All author affiliations should be entered
as follows:
1 University of London, London, UK; 2 University of Frankfurt, Frankfurt,
Germany; and 3 University of Paris, Paris, France.
Background
State the problem under investigation or a hypothesis. For therapeutic
agents, only generic names may be used (no trade names are permitted).
No figures or tables are allowed.
Methods
Explain the experimental methods used. For therapeutic agents, only
generic names may be used (no trade names are permitted). No figures
or tables are allowed.
Results
List the essential results obtained in summary form, with enough
quantitative data to permit evaluation by reviewers. For therapeutic
agents, only generic names may be used (no trade names are permitted).
No figures or tables are allowed.
Conclusion
Summarize the findings. It is unacceptable to use statements such
as "the results will be discussed". For therapeutic agents,
only generic names may be used (no trade names are permitted). No
figures or tables are allowed.
ADDITIONAL ABSTRACT INFORMATION
In addition to the uploaded abstract, the
following additional information will be collected on the abstract
submission form:
Abstract Category
For purposes of review and programming, abstracts are divided into
topical categories. Selection of the most appropriate category is
important as it determines who reviews your abstract. The Organizing
Committee reserves the right to reassign your abstract to a more
appropriate category.
· Resistance to New Antiretroviral
Agents
· Mechanisms of HIV Drug Resistance
· HIV Pathogenesis, Fitness and Resistance
· Clinical Implications of Resistance
· Epidemiology
· New Resistance Technologies and Interpretations
Abstract Title (should
be the same as in the uploaded abstract)
Use a short and concise title that indicates the content of the
abstract. Capitalize the first letter of each word except prepositions,
articles, and species names. Species names should be spelled out
at first use. Italicize scientific names of organisms (example:
Staphylococcus aureus). For therapeutic agents, only generic
names may be used (no trade names are permitted in abstract titles).
Keywords
Provide up to three keywords. These keywords are completely independent
of each other and should be able to stand alone in the index. Words
should be lowercase, except for genus names and proper nouns.
ABSTRACT EVALUATION AND SCORING
The Organizing Committee (OC) and 4-6 members of the Scientific
Committee (SC) will review each abstract. The OC evaluates all submitted
abstracts. Members of the SC are selected for abstract categories
based upon their individual expertise.
OC and SC members are instructed to review the abstracts for the
quality and originality of the work and to score them numerically.
All reviewers are instructed to abstain from scoring any abstract
on which they are an author/co-author, have a financial or personal
conflict of interest, or do not have the appropriate expertise to
evaluate.
Scores for each abstract are averaged and the standard deviation
is calculated to assess variability. If variability is high, outlier
scores are identified and censored.
Abstracts with high variability in scores are discussed individually.
PUBLISHED ABSTRACT BOOK
Accepted abstracts will be standardized in font and presentation.
Any scientific error that appears in the submitted abstract will
appear in the printed abstract.
Subject to availability, copies of the Abstract
Book will be available for sale after the Conference:
Informed Horizons, LLC
1860 Montreal Road, Suite 212
Tucker GA 30084
USA
Tel: +1 770 946 3480
Fax: +1 770 897 9639
Abstract
submission Deadline has Passed
| 
